BioBusiness

Outsourcing collaborations provide insight into the key drivers of market growth.

To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.

In a deal potentially worth more than $530 million, Amgen will use TScan Therapeutics’ target discovery platform to home in on novel targets for Crohn’s disease treatment.

The new partnership between Sandoz, a Novartis division, and Just – Evotec Biologics will aim to develop and manufacture multiple biosimilars.

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.

Private investors from Advent International and Warburg Pincus will operate the assets as an independent CDMO.

The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.

The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.

Aspect Biosystems and Novo Nordisk A/S have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics.

The leaked study summary found that Carvykti (ciltacabtagene autoleucel) reduced disease progression by 74%.

A report from Business Standard highlighted India’s recent growth in the pharma sector.

Merck will acquire Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, at a total equity valuation of $10.8 billion.

FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.

Under this partnership, the two companies will develop bioprinted tissue therapeutics for diabetes and obesity.

Ginkgo Bioworks has acquired StrideBio's AAV capsid discovery and engineering platform and has formed a partnership with WARF for development of next-gen cell therapies.

The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.

Will court challenges to FDA’s oversight authority open the door for multiple lawsuits to block agency decisions on all sides?

If approved, Johnson & Johnson would pay $8.9 billion to resolve all current and future claims in its ongoing talc litigation.

Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.

The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.

What can we take away from Pfizer's acquisition of Seagen?

Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely.

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.

CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.

Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.